Cyclooxygenase-2 inhibitors: a new therapeutic option in the treatment of macular edema after cataract surgery.
Two patients had uneventful phacoemulsification. After initial improvement, vision deteriorated because of cystoid macular edema (CME). In 1 patient, treatment with systemic nonsteroidal antiinflammatory drugs showed significant improvement in visual acuity but had to be discontinued because of side effects and a relapse of the disease. In the other patient, this therapy was not sufficient. Both patients were given valdecoxib, a cyclooxygenase-2 inhibitor. The new therapy was tolerated well and led to significant and stable improvement in visual acuity in both patients. To our knowledge, this is the first report of using a cyclooxygenase-2 inhibitor in the treatment of clinically significant CME.
Reis
Alexander
A
Reis Medical Institution, Principality of Liechtenstein, Germany. reis@augenwerk.li
Birnbaum
Florian
F
Hansen
Lutz L
LL
Reinhard
Thomas
T
D000368:Aged; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D019654:Lens Implantation, Intraocular; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D018918:Phacoemulsification; D011183:Postoperative Complications; D013449:Sulfonamides / Q000627:therapeutic use*; D014792:Visual Acuity; D000096926:Benzenesulfonamides
D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides